Cardior Pharmaceuticals GmbH clinical trials
Acquired by Novo Nordisk A/S, May 2, 2024 · source ↗
The registry lists 3 studies whose lead sponsor is Cardior Pharmaceuticals GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 26, 2026.
Before and after it joined Novo Nordisk A/S
- First submitted before Cardior Pharmaceuticals GmbH became part of Novo Nordisk A/S
- 3
- First submitted after Cardior Pharmaceuticals GmbH became part of Novo Nordisk A/S
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 2
- Withdrawn
- 1
Registry sponsor names on this page
- Cardior Pharmaceuticals GmbH3 studies
Something wrong with this grouping? Tell us on the Novo Nordisk A/S page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Novo Nordisk A/S studies →
- Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial InfarctionCompletedNCT05350969Phase 2
Sponsor listed in the registry: Cardior Pharmaceuticals GmbH · First submitted before Cardior Pharmaceuticals GmbH became part of Novo Nordisk A/S
- Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac HypertrophyWithdrawnNCT05953831Phase 2
Sponsor listed in the registry: Cardior Pharmaceuticals GmbH · First submitted before Cardior Pharmaceuticals GmbH became part of Novo Nordisk A/S
- Clinical Study to Assess Safety, PK and PD Parameters of CDR132LCompletedNCT04045405Phase 1
Sponsor listed in the registry: Cardior Pharmaceuticals GmbH · First submitted before Cardior Pharmaceuticals GmbH became part of Novo Nordisk A/S